XORTX Therapeutics (XRTX) Stock Overview
A late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XRTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
XORTX Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.40 |
| 52 Week High | CA$1.41 |
| 52 Week Low | CA$0.40 |
| Beta | 0.15 |
| 1 Month Change | -32.80% |
| 3 Month Change | -27.75% |
| 1 Year Change | -54.70% |
| 3 Year Change | -92.72% |
| 5 Year Change | -98.44% |
| Change since IPO | -97.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| XRTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -17.7% | 2.7% | -3.0% |
| 1Y | -54.7% | 25.4% | 10.3% |
Return vs Industry: XRTX underperformed the US Pharmaceuticals industry which returned 30.1% over the past year.
Return vs Market: XRTX underperformed the US Market which returned 12.3% over the past year.
Price Volatility
| XRTX volatility | |
|---|---|
| XRTX Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XRTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XRTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Allen Davidoff | www.xortx.com |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance.
XORTX Therapeutics Inc. Fundamentals Summary
| XRTX fundamental statistics | |
|---|---|
| Market cap | US$3.46m |
| Earnings (TTM) | -US$1.94m |
| Revenue (TTM) | n/a |
Is XRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.94m |
| Earnings | -US$1.94m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XRTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 02:10 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
XORTX Therapeutics Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |